Fibrocell Science (NASDAQ: FCSC) and Sunesis Pharmaceuticals (NASDAQ:SNSS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.
Volatility & Risk
Fibrocell Science has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, Sunesis Pharmaceuticals has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500.
31.6% of Fibrocell Science shares are owned by institutional investors. Comparatively, 38.2% of Sunesis Pharmaceuticals shares are owned by institutional investors. 2.1% of Fibrocell Science shares are owned by company insiders. Comparatively, 10.2% of Sunesis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This table compares Fibrocell Science and Sunesis Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and target prices for Fibrocell Science and Sunesis Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Fibrocell Science currently has a consensus target price of $5.00, suggesting a potential upside of 594.44%. Sunesis Pharmaceuticals has a consensus target price of $4.16, suggesting a potential downside of 1.89%. Given Fibrocell Science’s stronger consensus rating and higher probable upside, analysts clearly believe Fibrocell Science is more favorable than Sunesis Pharmaceuticals.
Earnings and Valuation
This table compares Fibrocell Science and Sunesis Pharmaceuticals’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Fibrocell Science||$350,000.00||53.28||-$15.29 million||($1.83)||-0.39|
|Sunesis Pharmaceuticals||$2.54 million||57.17||-$38.02 million||($1.75)||-2.42|
Fibrocell Science has higher earnings, but lower revenue than Sunesis Pharmaceuticals. Sunesis Pharmaceuticals is trading at a lower price-to-earnings ratio than Fibrocell Science, indicating that it is currently the more affordable of the two stocks.
Sunesis Pharmaceuticals beats Fibrocell Science on 7 of the 13 factors compared between the two stocks.
About Fibrocell Science
Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.
About Sunesis Pharmaceuticals
Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company’s other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton’s tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.